Fungicidal effect by regulating signal transduction pathways

• US 20060293381A1
• Filed: 06/22/2006
• Published: 12/28/2006
• Est. Priority Date: 06/23/2005
• Status: Abandoned Application

• Current Assignee: Duke University
• Original Assignee: Duke University
• Inventors: Bahn, Yong-Sun, Kojima, Kaihei, Heitman, Joseph
• Application Number:
  US11/472,856
• Publication Number:
  US 20060293381A1
• Time in Patent Office: Days
• US Class Current: 514/422
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/4025 not condensed and containing further heterocyclic rings, e.g. cromakalim
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present invention concerns methods of treating fungal infections and methods of screening compounds for activity in treating fungal infections. Methods of the invention include using an active compound such as fludioxonil to treat a Cryptococcus neoformans infection. Also included are methods and pharmaceutical compositions useful for treating fungal infections using a Hog1 activator such as fludioxonil and a calcineurin inhibitor in combination.

Claims

1. A method of treating a Cryptococcus neoformans infection (or cryptococcosis) in a subject in need thereof, comprising administering an active agent to said subject in a treatment-effective amount;

wherein said active agent is fludioxonil, an analog thereof, or a pharmaceutically acceptable salt or prodrug thereof.

2. The method of claim 1, wherein said subject is an immune impaired subject.

3. A pharmaceutical composition useful for treating cryptococcosis comprising an active agent in a pharmaceutically acceptable carrier;

wherein said active agent is fludioxonil, an analog thereof, or a pharmaceutically acceptable salt or prodrug thereof.

4. A method of treating a fungal infection in a subject in need thereof, comprising administering said subject, in combination:

a. a Hog1 activator; and

b. a calcineurin inhibitor.

5. The method of claim 4, wherein said fungal infection is cryptococcosis.

6. The method of claim 4, wherein said Hog1 activator is is fludioxonil, an analog thereof, or a pharmaceutically acceptable salt or prodrug thereof.

7. The method of claim 4, wherein said calcineurin inhibitor is FK506 or a pharmaceutically acceptable salt or prodrug thereof.

8. The method of claim 4, wherein said Hog1 activator and said calcineurin inhibitor are administered to said subject in a synergistically effective amount.

9. A pharmaceutical composition useful for treating a fungal infection comprising, in a pharmaceutically acceptable carrier,

a. a Hog1 activator;

and

b. a calcineurin inhibitor.

10. The composition of claim 9, wherein said Hog1 activator is is fludioxonil, an analog thereof, or a pharmaceutically acceptable salt or prodrug thereof.

11. The composition of claim 9, wherein said calcineurin inhibitor is FK506 or a pharmaceutically acceptable salt or prodrug thereof.

12. A method of screening a compound for fungicidal activity, comprising:

a. contacting a fungal cell containing Hog1 to said compound; and

then

b. detecting activation of Hog1 by said compound, activation of Hog1 indicating fungicidal activity of said compound.

13. The method of claim 12, wherein said fungal cell is a Cryptococcus neoformans cell.

14. The method of claim 12, wherein said Hog1 activation is detected by detecting glycerol accumulation in said cell.